Details of the Drug Formulation (DFM)

General Information of DFM (ID: F21753)
Name
Ursodeoxycholic acid 300 mg capsule
Company
A-S Medication Solutions; Actavis Pharma; Carilion Materials Management; Physicians Total Care; Preferred Pharamaceuticals
Active Pharmaceutical Ingredient (API) Ursodeoxycholic acid API Info click to show the detail info of this API
Hepatic fibrosis/cirrhosis ICD-11: DB93 Approved
Drug Inactive Ingredient (DIGs)
DIG ID DIG Info DIG Name DIG Functional Class
E09YYN DIG Info Eisenoxyd Colorant
E02FBG DIG Info Ferrosoferric oxide Colorant
E01UTP DIG Info Magnesium stearate lubricant
E01UTV DIG Info Silicon dioxide Anticaking agent ...
Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM
      Oxidoreductase (ORase)
            DBT Name: Albendazole monooxygenase (CYP3A4) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment (1) for Assessing the Biological Activity of the Studied DIG on This DBT
                    Interacting DIG Magnesium stearate
                    Biological Activity Protein expression downregulation (tested by experiment) [1]
                    Tested Species Homo sapiens (Human)
                    UniProt ID CP3A4_HUMAN
               Experiment (2) for Assessing the Biological Activity of the Studied DIG on This DBT
                    Interacting DIG Silicon dioxide
                    Biological Activity Protein expression downregulation (tested by experiment) [1]
                    Tested Species Homo sapiens (Human)
                    UniProt ID CP3A4_HUMAN
References
1 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.